blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2636677

EP2636677 - CDK-INHIBITING PYRROLOPYRIMIDINONE CARBOXAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING LIVER CELL CANCER [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  18.11.2016
Database last updated on 19.10.2024
Most recent event   Tooltip12.10.2018Lapse of the patent in a contracting state
New state(s): AL		published on 14.11.2018  [2018/46]
Applicant(s)For all designated states
SNU R&DB Foundation
San 56-1 Sillim-dong
Gwanak-gu
Seoul 151-742 / KR
[2016/02]
Former [2013/37]For all designated states
SNU R & DB Foundation
San 56-1 Sillim-dong
Gwanak-gu, Seoul 151-742 / KR
Inventor(s)01 / LEE, Seung Ki
101-405 Gyungnam Anusvill Apt.
722 Yeoksam-2dong
Gangnam-gu
Seoul 135-920 / KR
02 / KIM, Byeong Moon
302-1106 Nakseongdae Hyundai Hometown Apt.
Haengun-dong
Gwanak-gu
Seoul 151-728 / KR
03 / CHO, Seung Ju
203-208 Jugong 2-Danji Apt.
Wolpi-dong
Sangnok-gu
Ansan-si Gyeonggi-do 426-786 / KR
04 / KIM, Young Jong
103 Seongmun Campustel
207-14 Nakseongdae-dong
Gwanak-gu
Seoul 151-851 / KR
 [2013/37]
Representative(s)Brady, Paul Andrew, et al
Abel & Imray
20 Red Lion Street
London WC1R 4PQ / GB
[2013/37]
Application number, filing date10859285.802.11.2010
[2016/02]
WO2010KR07650
Filing languageKO
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2012060482
Date:10.05.2012
Language:KO
[2012/19]
Type: A1 Application with search report 
No.:EP2636677
Date:11.09.2013
Language:EN
[2013/37]
Type: B1 Patent specification 
No.:EP2636677
Date:13.01.2016
Language:EN
[2016/02]
Search report(s)International search report - published on:KR10.05.2012
(Supplementary) European search report - dispatched on:EP14.03.2014
ClassificationIPC:C07H19/14, A61K31/7068, A61P35/00
[2013/37]
CPC:
C07H19/14 (EP,US); A61K31/519 (EP,US); A61K31/7068 (EP,US);
A61P35/00 (EP); C07H1/00 (US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/37]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:CDK-HEMMENDES PYRROLOPYRIMIDINONCARBOXAMIDDERIVAT ODER PHARMAZEUTISCH AKZEPTABLES SALZ DARAUS UND DIESE ENTHALTENDE PHARMAZEUTISCHE ZUSAMMENSETZUNG ZUR PRÄVENTION ODER BEHANDLUNG VON LEBERZELLENKARZINOM[2013/37]
English:CDK-INHIBITING PYRROLOPYRIMIDINONE CARBOXAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING LIVER CELL CANCER[2013/37]
French:DÉRIVÉ DE CARBOXAMIDE DE PYRROLOPYRIMIDINONE INHIBANT LES CDK OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, ET COMPOSITION PHARMACEUTIQUE CONTENANT CE DÉRIVÉ COMME PRINCIPE ACTIF ET DESTINÉE À PRÉVENIR OU À TRAITER UN CARCINOME HÉPATOCELLULAIRE[2013/37]
Entry into regional phase24.05.2013Translation filed 
24.05.2013National basic fee paid 
24.05.2013Search fee paid 
24.05.2013Designation fee(s) paid 
24.05.2013Examination fee paid 
Examination procedure24.05.2013Examination requested  [2013/37]
02.09.2014Amendment by applicant (claims and/or description)
03.08.2015Communication of intention to grant the patent
13.11.2015Fee for grant paid
13.11.2015Fee for publishing/printing paid
13.11.2015Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  03.08.2015
Opposition(s)14.10.2016No opposition filed within time limit [2016/51]
Fees paidRenewal fee
24.05.2013Renewal fee patent year 03
18.11.2013Renewal fee patent year 04
10.11.2014Renewal fee patent year 05
10.11.2015Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU02.11.2010
AL13.01.2016
AT13.01.2016
BE13.01.2016
CY13.01.2016
CZ13.01.2016
DK13.01.2016
EE13.01.2016
ES13.01.2016
FI13.01.2016
HR13.01.2016
IT13.01.2016
LT13.01.2016
LV13.01.2016
MC13.01.2016
MK13.01.2016
NL13.01.2016
PL13.01.2016
RO13.01.2016
RS13.01.2016
SE13.01.2016
SI13.01.2016
SK13.01.2016
SM13.01.2016
TR13.01.2016
BG13.04.2016
NO13.04.2016
GR14.04.2016
IS13.05.2016
PT13.05.2016
[2018/46]
Former [2018/45]HU02.11.2010
AT13.01.2016
BE13.01.2016
CY13.01.2016
CZ13.01.2016
DK13.01.2016
EE13.01.2016
ES13.01.2016
FI13.01.2016
HR13.01.2016
IT13.01.2016
LT13.01.2016
LV13.01.2016
MC13.01.2016
MK13.01.2016
NL13.01.2016
PL13.01.2016
RO13.01.2016
RS13.01.2016
SE13.01.2016
SI13.01.2016
SK13.01.2016
SM13.01.2016
TR13.01.2016
BG13.04.2016
NO13.04.2016
GR14.04.2016
IS13.05.2016
PT13.05.2016
Former [2018/28]HU02.11.2010
AT13.01.2016
BE13.01.2016
CY13.01.2016
CZ13.01.2016
DK13.01.2016
EE13.01.2016
ES13.01.2016
FI13.01.2016
HR13.01.2016
IT13.01.2016
LT13.01.2016
LV13.01.2016
MC13.01.2016
MK13.01.2016
NL13.01.2016
PL13.01.2016
RO13.01.2016
RS13.01.2016
SE13.01.2016
SI13.01.2016
SK13.01.2016
SM13.01.2016
BG13.04.2016
NO13.04.2016
GR14.04.2016
IS13.05.2016
PT13.05.2016
Former [2017/16]AT13.01.2016
BE13.01.2016
CZ13.01.2016
DK13.01.2016
EE13.01.2016
ES13.01.2016
FI13.01.2016
HR13.01.2016
IT13.01.2016
LT13.01.2016
LV13.01.2016
NL13.01.2016
PL13.01.2016
RO13.01.2016
RS13.01.2016
SE13.01.2016
SI13.01.2016
SK13.01.2016
SM13.01.2016
BG13.04.2016
NO13.04.2016
GR14.04.2016
IS13.05.2016
PT13.05.2016
Former [2017/03]AT13.01.2016
BE13.01.2016
CZ13.01.2016
DK13.01.2016
EE13.01.2016
ES13.01.2016
FI13.01.2016
HR13.01.2016
IT13.01.2016
LT13.01.2016
LV13.01.2016
NL13.01.2016
PL13.01.2016
RO13.01.2016
RS13.01.2016
SE13.01.2016
SK13.01.2016
SM13.01.2016
NO13.04.2016
GR14.04.2016
IS13.05.2016
PT13.05.2016
Former [2016/50]AT13.01.2016
CZ13.01.2016
DK13.01.2016
EE13.01.2016
ES13.01.2016
FI13.01.2016
HR13.01.2016
IT13.01.2016
LT13.01.2016
LV13.01.2016
NL13.01.2016
PL13.01.2016
RO13.01.2016
RS13.01.2016
SE13.01.2016
SK13.01.2016
SM13.01.2016
NO13.04.2016
GR14.04.2016
IS13.05.2016
PT13.05.2016
Former [2016/49]AT13.01.2016
DK13.01.2016
EE13.01.2016
ES13.01.2016
FI13.01.2016
HR13.01.2016
IT13.01.2016
LT13.01.2016
LV13.01.2016
NL13.01.2016
PL13.01.2016
RS13.01.2016
SE13.01.2016
NO13.04.2016
GR14.04.2016
IS13.05.2016
PT13.05.2016
Former [2016/46]AT13.01.2016
DK13.01.2016
ES13.01.2016
FI13.01.2016
HR13.01.2016
IT13.01.2016
LT13.01.2016
LV13.01.2016
NL13.01.2016
PL13.01.2016
RS13.01.2016
SE13.01.2016
NO13.04.2016
GR14.04.2016
IS13.05.2016
PT13.05.2016
Former [2016/39]AT13.01.2016
ES13.01.2016
FI13.01.2016
HR13.01.2016
IT13.01.2016
LT13.01.2016
LV13.01.2016
NL13.01.2016
PL13.01.2016
RS13.01.2016
SE13.01.2016
NO13.04.2016
GR14.04.2016
IS13.05.2016
PT13.05.2016
Former [2016/38]AT13.01.2016
ES13.01.2016
FI13.01.2016
HR13.01.2016
IT13.01.2016
LT13.01.2016
NL13.01.2016
PL13.01.2016
NO13.04.2016
GR14.04.2016
IS13.05.2016
PT13.05.2016
Former [2016/36]AT13.01.2016
ES13.01.2016
FI13.01.2016
HR13.01.2016
IT13.01.2016
LT13.01.2016
NL13.01.2016
PL13.01.2016
NO13.04.2016
GR14.04.2016
Former [2016/35]ES13.01.2016
FI13.01.2016
HR13.01.2016
NL13.01.2016
NO13.04.2016
GR14.04.2016
Former [2016/30]NL13.01.2016
Documents cited:Search[I]  - HUANG B-G ET AL, "Synthesis and in vitro antitumor activity of some amino-deoxy 7-hexofuranosylpyrrolo[2,3-d]pyrimidines", CARBOHYDRATE RESEARCH, PERGAMON, GB, (19980401), vol. 308, no. 3-4, doi:10.1016/S0008-6215(98)00098-6, ISSN 0008-6215, pages 319 - 328, XP004181394 [I] 1-10 * the whole document *

DOI:   http://dx.doi.org/10.1016/S0008-6215(98)00098-6
 [I]  - ANDERSON, JACK D. ET AL, "Synthesis of tubercidin, 6-chlorotubercidin and related nucleosides", CAPLUS, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, Database accession no. 1990:139716, URL: STN, XP002721101 [I] 1-10 * abstract *

DOI:   http://dx.doi.org/10.1080/07328318908054327
    [ ] - ANDERSON, JACK D. ET AL, "Synthesis of tubercidin, 6-chlorotubercidin and related nucleosides", NUCLEOSIDES & NUCLEOTIDES ( 1989 ), 8(7), 1201-16 CODEN: NUNUD5; ISSN: 0732-8311, (1989), doi:10.1080/07328318908054327
International search[A]US2002035077  (TAM ROBERT [US], et al);
 [A]US2009117651  (GARTEL ANDREI [US], et al);
 [A]  - HAM Y.-M. ET AL., "Xylocydine, a Novel Inhibitor of Cyclin-Dependent Kinases, Prevents the Tumor Necrosi: Factor-Related Apoptosis- Inducing Ligand-Induced Apoptotic Cell Death of SK-HEP-1 Cells", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, (2004), vol. 308, no. 2, pages 814 - 819, XP055089517

DOI:   http://dx.doi.org/10.1124/jpet.103.059568
 [A]  - CHO S.-J. ET AL., "Xylocydine, a novel Cdk inhibitor, is an effective inducer of apoptosis in hepatocellular carcinoma cells in vitro and in vivo", CANCER LETTERS, (20100128), vol. 287, pages 196 - 206, XP026824293
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.